Skip to main content
SpringerLink
Log in

Management of Benign Prostatic Hyperplasia

Defining the Roles of Terazosin and Finasteride

  • Drugs in Disease Management
  • Published:
Disease Management & Health Outcomes

Summary

Benign prostatic hyperplasia (BPH) affects men with increasing frequency as they age. The course of BPH is highly variable and not all men develop symptoms.

For most patients with mild symptoms of BPH, regular monitoring and reassessment (watchful waiting) are most appropriate. For those with moderate to severe symptoms, surgery [usually transurethral resection of the prostate (TURP)] or drug therapy (with finasteride or α1-receptor antagonists such as terazosin) are most frequently used. Surgery is indicated for men with complicated BPH.

Both terazosin and finasteride reduce voiding (obstructive) and total symptom scores and improve parameters of urinary function such as peak urinary flow rates in men with symptomatic BPH. However, results from a comparative trial of these agents show terazosin to be more effective than finasteride in reducing symptoms and increasing urinary flow rates. Although the study has been criticised for not stratifying patients by baseline prostate volumes and for the low mean prostate volumes of study participants, the findings have subsequently been confirmed in a subset of men with large prostates (>50ml).

In common with other α1-receptor antagonists, terazosin reduces smooth muscle tone and contraction in the bladder neck and prostate, which results in a decrease in urethral pressure. The drug does not reduce prostate volume and efficacy is not influenced by prostate size. Terazosin has favourable effects on blood pressure and the lipid profile.

Finasteride acts by inhibiting the 5α-reductase enzyme in the prostate, thus reducing circulating levels of dihydrotestosterone, the androgen primarily responsible for prostatic enlargement. Consequently, finasteride reduces prostate volume and the drug has been thought to be most effective in men with a prostate volume ≥40 or 50ml; however, whether baseline prostate volume is an accurate predictor of response to pharmacotherapy has now been questioned. Finasteride has a slow onset of action compared with terazosin (≈6 months versus a few weeks), but preliminary evidence indicates that disease progression may be halted or reversed when finasteride is used long term (≥2 years). Furthermore, finasteride has been shown to reduce the incidence of acute urinary retention and surgical intervention associated with BPH.

In men with symptomatic BPH, there are few clear-cut criteria for initiation of treatment or for predicting which treatment will be most beneficial. The long term costs and benefits of various treatment options remain to be fully determined. On the basis of available data, terazosin may be used in patients with moderate to severe symptomatic BPH irrespective of prostate size; this agent may be particularly useful in men with concomitant hypertension. Finasteride appears to be best limited to patients with a prostate volume ≥40 or 50ml. Symptomatic improvement appears to be greater with terazosin than with finasteride, whereas finasteride is the only agent, to date, which has been shown to halt or reverse disease progression and reduce surgical intervention and acute urinary retention in this patient group. In the final analysis, treatment decisions must be individualised and guided by clinical experience and judgement as well as patient preference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McConnell JD. Benign prostatic hyperplasia: treatment guidelines and patient classification. Br J Urol 1995 Jul; 76 Suppl. 1: 29–46

    PubMed  Google Scholar 

  2. Roehrborn CG. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am 1995 May; 22: 445–53

    PubMed  CAS  Google Scholar 

  3. Roberts RG. BPH: new guidelines based on symptoms and patient preference. The Agency for Health Care Policy and Research [see comments]. Geriatrics 1994 Jul; 49: 24–31

    PubMed  CAS  Google Scholar 

  4. Shapiro E, Lepor H. The pathophysiology of clinical BPH. Prog Clin Biol Res 1994; 386: 253–61

    PubMed  CAS  Google Scholar 

  5. Griffiths K, Eaton CL. The pathogenesis of BPH: role of hormones. Prog Clin Biol Res 1994; 386: 33–41

    PubMed  CAS  Google Scholar 

  6. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992; 14: 131–53

    PubMed  CAS  Google Scholar 

  7. Habib FK. The role of growth factors in the pathogenesis of BPH. Prog Clin Biol Res 1994; 386: 43–50

    PubMed  CAS  Google Scholar 

  8. Bruskewitz RC. Benign prostatic hyperplasia: drug and non-drug therapies. Geriatrics 1992 Dec; 47: 39–42, 45

    PubMed  CAS  Google Scholar 

  9. Andersen JT. α-1-blockers vs 5-α-reductase inhibitors in benign prostatic hyperplasia: a comparative review. Drugs Aging 1995 May; 6: 388–96

    Article  PubMed  CAS  Google Scholar 

  10. Moul JW. Benign prostatic hyperplasia. New concepts in the 1990s [see comments]. Postgrad Med 1993 Nov 1; 94: 141-6, 151–2

    Google Scholar 

  11. Appell RA. Pathogenesis and medical management of benign prostatic hyperplasia. Semin Nephrol 1994 Nov; 14: 531–43

    PubMed  CAS  Google Scholar 

  12. Peters DH, Sorkin EM. Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993 Jul; 46: 177–208

    Article  PubMed  CAS  Google Scholar 

  13. Eri LM, Tveter KJ. Treatment of benign prostatic hyperplasia: a pharmacoeconomic perspective. Drugs Aging 1997 Feb 10; 10(2): 107–18

    Article  PubMed  CAS  Google Scholar 

  14. Cameron-Strange A. Benign prostatic hypertrophy. Curr Ther 1996 Feb; 37: 45–51

    Google Scholar 

  15. Prostatic Hyperplasia Guideline Panel. Benign prostatic hyperplasia: diagnosis and treatment: quick reference for clinicians. J Pharm Care Pain Symptom Control 1995; 3(1): 57–74

    Article  Google Scholar 

  16. Finasteride: good tolerability but modest clinical benefit in BPH. Drug Ther Perspect 1993 Aug 30; 2 (4): 1-4

  17. O’Leary MP. Epidemiology of benign prostatic hyperplasia. Br J Urol 1995 Jul; 76 Suppl. 1: 1–3

    PubMed  Google Scholar 

  18. Boyle P. New insights into the epidemiology and natural history of benign prostatic hyperplasia. Prog Clin Biol Res 1994; 386: 3–18

    PubMed  CAS  Google Scholar 

  19. Boyle P, McGinn R, Maisonneuve P, et al. Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol 1991; 20 Suppl. 21: 3–10

    PubMed  Google Scholar 

  20. Stricker PD. Drug treatment of benign prostatic hypertrophy. Med Dig 1996 Jun; 22: 16–20

    Google Scholar 

  21. Oesterling JE. Benign prostatic hyperplasia: choosing the best therapy for each patient. J Clin Outcome Manage 1996 Jan–Feb; 3: 43–50

    Google Scholar 

  22. Benign prostatic hyperplasia. Effective Health Care 1995; 2(2): 1–16

    Google Scholar 

  23. McDade T. Prostates and profits: the social construction of benign prostatic hyperplasia in American men. Med Anthropol 1996 May; 17: 1–22

    Article  PubMed  CAS  Google Scholar 

  24. Hunter DJ, McKee CM, Sanderson CF, et al. Appropriate indications for prostatectomy in the UK — results of a consensus panel. J Epidemiol Community Health 1994 Feb; 48: 58–64

    Article  PubMed  CAS  Google Scholar 

  25. Benign prostatic hyperplasia: diagnosis and treatment: guideline overview. J Natl Med Assoc 1994 Jul; 86: 489

    Google Scholar 

  26. Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med 1995 Jan 12; 332: 99–109

    Article  PubMed  CAS  Google Scholar 

  27. Jonler M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia. Current pharmacological treatment. Drugs 1994 Jan; 47: 66–81

    Article  PubMed  CAS  Google Scholar 

  28. Fitzpatrick JM, Lynch TH. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 1995 May; 22: 407–12

    PubMed  CAS  Google Scholar 

  29. Plosker GL, Brogden RN. Serenoa repens (Permixon®): a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996 Nov; 9: 379–95

    Article  PubMed  CAS  Google Scholar 

  30. Barry MJ, Fowler FJ Jr, O’Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care 1995 Apr; 33 (4 Suppl.): AS145–55

    PubMed  CAS  Google Scholar 

  31. Gee WF, Holtgrewe HL, Albertsen PC, et al. Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 1995 Jul; 154: 205–6

    Article  PubMed  CAS  Google Scholar 

  32. Stoner E, and the Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 292–9

    Google Scholar 

  33. Gormeley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–91

    Article  Google Scholar 

  34. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996 Sep; 48: 398–405

    Article  PubMed  CAS  Google Scholar 

  35. Roehrborn CG, Oesterling JE, Auerbach S. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996 Feb; 47: 159–68

    Article  PubMed  CAS  Google Scholar 

  36. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995 May; 22: 375–86

    PubMed  CAS  Google Scholar 

  37. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995 Sep; 154: 923–34

    Article  PubMed  CAS  Google Scholar 

  38. Lepor H, Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995 Mar; 45: 406–13

    Article  PubMed  CAS  Google Scholar 

  39. Lepor H, Willifird W. Factors predicting response to medical therapy for BPH: an analysis of the V.A. study [abstract no. 810]. Br J Urol 1997; 80 Suppl. 2: 207

    Google Scholar 

  40. Hamdy FC, Chopin DK, Authie D, et al. Prostatic volume does not correlate with efficacy of treatment for mild to moderate benign prostatic hyperplasia using either finasteride or phytotherapy (Permixon) [abstract no. 760]. Br J Urol 1997; 80 Suppl. 2: 195

    Google Scholar 

  41. Roylance P, Gibelin B, Espié J. Current treatment of BPH. Biomed Pharmacother 1995; 49: 332–8

    Article  PubMed  CAS  Google Scholar 

  42. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995 Feb; 49: 295–320

    Article  PubMed  CAS  Google Scholar 

  43. Wilde MI, Fitton A, McTavish D. Alfuzosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993 Mar; 45: 410–29

    Article  PubMed  CAS  Google Scholar 

  44. Wilde MI, McTavish D. Tamsulosin: a review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996 Dec; 52: 883–98

    Article  PubMed  CAS  Google Scholar 

  45. Finasteride prescribing information. In: McEvoy GK, editor. American Hospital Formulary Service Drug Information. Bethesda: American Society of Health-System Pharmacists, 1996; 2734–6

    Google Scholar 

  46. Finasteride prescribing information. In: Walker G, editor. ABPI compendium of data sheets and summaries of product characteristics. London: Datapharm Publications Limited, 1996; 949–50

    Google Scholar 

  47. Wilde MI, Fitton A, Sorkin EM. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993 May–Jun; 3: 258–77

    Article  PubMed  CAS  Google Scholar 

  48. Terazosin prescribing information. In: Walker G, editor. ABPI compendium of data sheets and summaries of product characteristics. London: Datapharm Publications Limited, 1996: 11–4

    Google Scholar 

  49. Terazosin hydrochloride prescribing information. In: McEvoy GK, editor. American Hospital Formulary Service Drug Information. Bethesda: American Society of Health-System Pharmacists, 1996: 1326–8

    Google Scholar 

  50. Cauffield JS, Gums JG, Whit CJ. Alpha blockers: a reassessment of their role in therapy. Am Fam Physician 1996 Jul; 54: 263–70

    PubMed  CAS  Google Scholar 

  51. Kaplan SA, Kaplan NM. Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia. Urology 1996 Oct; 48: 541–50

    Article  PubMed  CAS  Google Scholar 

  52. Rittmaster RS. Finasteride. N Engl J Med 1994 Jan 13; 330: 120–5

    Article  PubMed  CAS  Google Scholar 

  53. Stoner E. 5 α-Reductase inhibitors/finasteride. Prostate 1996 Suppl. 6: 82–7

    Article  PubMed  CAS  Google Scholar 

  54. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 1996 Nov 1; 155: 1251–9

    CAS  Google Scholar 

  55. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995 Nov; 46: 631–7

    Article  PubMed  CAS  Google Scholar 

  56. Tenover JL, Pagano GA, Morton AS, et al. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther 1997; 19(2): 243–58

    Article  PubMed  CAS  Google Scholar 

  57. Stoner E, Andriole GL, Boake R, et al. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994 Mar; 43: 284–94

    Article  PubMed  CAS  Google Scholar 

  58. Moore E, Bracken B, Bremner W, et al. Proscar: five-year experience. Eur Urol 1995; 28: 304–9

    PubMed  CAS  Google Scholar 

  59. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49: 839–45

    Article  PubMed  CAS  Google Scholar 

  60. Long-term BPH benefit with finasteride. Scrip 1997 Oct 3 (2272): 20

  61. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996 Aug 22; 335: 533–9

    Article  PubMed  CAS  Google Scholar 

  62. Walsh PC. Treatment of benign prostatic hyperplasia. N Engl J Med 1996 Aug 22; 335: 586–7

    Article  PubMed  CAS  Google Scholar 

  63. Boyle P. Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension. Br J Clin Pract Symp Suppl 1994 May; 74: 18–22

    CAS  Google Scholar 

  64. Wasson JH, Baczek LA, Ducharme JY, et al. Comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993 Nov; 150: 1696–700

    Google Scholar 

  65. Vale JA, Bdesha AS, Witherow RO. An analysis of the costs of alternative treatments for benign prostatic hypertrophy. J R Soc Med 1995 Nov; 88: 644P–8P

    PubMed  CAS  Google Scholar 

  66. Ahlstrand C, Carlsson P, Jönsson B. Estimated total costs of treating benign prostatic hyperplasia in Sweden. Scand J Urol Nephral 1995 Mar; 29: 57–63

    Article  CAS  Google Scholar 

  67. Girman CJ, Kolman C, Liss CL, et al. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Prostate 1996 Aug; 29: 83–90

    Article  PubMed  CAS  Google Scholar 

  68. Baladi J-F, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. PharmacoEconomics 1996 May; 9: 443–54

    Article  CAS  Google Scholar 

  69. Plosker GL, Goa KL. Terazosin: a pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. PharmacoEconomics 1997 Feb; 11: 184–97

    Article  CAS  Google Scholar 

  70. Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996 Feb; 47: 169–78

    Article  PubMed  CAS  Google Scholar 

  71. Drummond MF, McGuire AJ, Black NA, et al. Economic burden of treated benign prostatic hyperplasia in the United Kingdom. Br J Urol 1993 Mar; 71: 290–6

    Article  PubMed  CAS  Google Scholar 

  72. Scott WG, Scott HM. Annual costs of benign prostatic hyperplasia in New Zealand. PharmacoEconomics 1993 Dec; 4: 455–68

    Article  CAS  Google Scholar 

  73. Lowe FC, McDaniel RL, Chmiel JJ, et al. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995 Oct; 46(4): 477–83

    Article  PubMed  CAS  Google Scholar 

  74. Cockrum PC, Finder SF, Ries AJ, et al. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. PharmacoEconomics 1997; 11(6): 550–65

    Article  CAS  Google Scholar 

  75. Roehrborn CG. Some socio-economic issues surrounding prostatectomy: the US experience. Prog Clin Biol Res 1994; 386: 419–25

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand

    Jane C. Gillis & Michelle I. Wilde

Authors
  1. Jane C. Gillis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle I. Wilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle I. Wilde.

Additional information

Various sections of the manuscript reviewed by: R.A. Appell, Department of Urology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA; L.M. Eri, Department of Urology, Ullevaal University Hospital, Oslo, Norway; M. Jønler, Hjerte-lunge-karkirurgisk afdeling, Skejby Sygehus, Arhus Universitetshospital, Viborg, Denmark; J.C. Nickel, Department of Urology, Queen’s University, Kingston General Hospital, Kingston, Ontario, Canada; R.S. Rittmaster, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; T. Tammela, Division of Urology, Tampere University Hospital, Tampere, Finland

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gillis, J.C., Wilde, M.I. Management of Benign Prostatic Hyperplasia. Dis-Manage-Health-Outcomes 2, 302–317 (1997). https://doi.org/10.2165/00115677-199702060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-199702060-00005

Keywords

Search

Navigation